← FDA DRUG APPROVALS

FDA ANDA · ANDA075373

BETAMETHASONE DIPROPIONATE

Sponsor: FOUGERA PHARMS

APPLICATION
ANDA075373
TYPE
ANDA
ORIGINAL APPROVAL
1999-06-22
LATEST ACTION
2020-06-09
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT, AUGMENTED
MARKETING STATUS
Prescription

Products

BETAMETHASONE DIPROPIONATEPrescription
BETAMETHASONE DIPROPIONATE EQ 0.05% BASE · OINTMENT, AUGMENTED · TOPICAL

Approval history

2020-06-09Labeling · Supplement 12 · standardAP
2020-06-09Labeling · Supplement 11 · standardAP
2016-05-12Labeling · Supplement 8 · standardAP
2016-05-12Labeling · Supplement 9 · standardAP
1999-06-22OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →